{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:23:21Z","timestamp":1791555801377,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.dld.2021.07.015","type":"journal-article","created":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T05:57:37Z","timestamp":1628315857000},"page":"1396-1403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"53","author":[{"given":"Peter D.","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minnie","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Tee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad A","family":"Chinnaratha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dld.2021.07.015_bib0001","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.gastro.2019.03.070","article-title":"AGA clinical practice update: coagulation in cirrhosis","volume":"157","author":"O'Leary","year":"2019","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.dld.2021.07.015_bib0002","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/hep4.1423","article-title":"Thrombocytopenia and procedural prophylaxis in the era of thrombopoietin receptor agonists","volume":"3","author":"Nilles","year":"2019","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.dld.2021.07.015_bib0003","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cgh.2009.02.021","article-title":"Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis","volume":"7","author":"Qamar","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.dld.2021.07.015_bib0004","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","article-title":"Thrombocytopenia associated with chronic liver disease","volume":"48","author":"Afdhal","year":"2008","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2021.07.015_bib0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.21231","article-title":"Elevated levels of von willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity","volume":"44","author":"Lisman","year":"2006","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.dld.2021.07.015_bib0006","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cgh.2010.06.018","article-title":"Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease","volume":"8","author":"Giannini","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.07.015_bib0007","first-page":"1491","article-title":"Proceedings of the concepts and controversies in haemostasis and thrombosis associated with liver disease: proceedings of the 7th international coagulation in liver disease conference","author":"Intagliata","year":"2018"},{"issue":"2","key":"10.1016\/j.dld.2021.07.015_bib0008","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/hep.21266","article-title":"Thrombin generation in patients with cirrhosis: the role of platelets","volume":"44","author":"Tripodi","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dld.2021.07.015_bib0009","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.dld.2021.07.015_bib0010","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199809103391107","article-title":"Thrombopoietin","volume":"339","author":"Kaushansky","year":"1998","journal-title":"N. Eng. J. Med."},{"issue":"25","key":"10.1016\/j.dld.2021.07.015_bib0011","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","article-title":"A randomized trial of avatrombopag, an investigational thrombopoietin- receptor agonist, in persistent and chronic immune thrombocytopenia","volume":"123","author":"Bussel","year":"2014","journal-title":"Blood"},{"issue":"9763","key":"10.1016\/j.dld.2021.07.015_bib0012","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"issue":"9664","key":"10.1016\/j.dld.2021.07.015_bib0013","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.dld.2021.07.015_bib0014","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.dld.2021.07.015_bib0015","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.dld.2021.07.015_bib0016","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1110709","article-title":"Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia","volume":"367","author":"Afdhal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.07.015_bib0017","unstructured":"U. S. Food & Drug Administration. Drug trial snapshot: mulpleta | FDA [Internet]. 2018 [cited 2020 Apr 20]; Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trial-snapshot-mulpleta"},{"key":"10.1016\/j.dld.2021.07.015_bib0018","unstructured":"U. S. Food & Drug Administration. Drug trial snapshot: doptelet [Internet]. 2018 [cited 2020 Apr 20]; Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trial-snapshot-doptelet"},{"key":"10.1016\/j.dld.2021.07.015_bib0019","unstructured":"European Medicines Agency. Mulpleo (previously Lusutrombopag Shionogi) [Internet]. 2019 [cited 2020 Apr 20]; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mulpleo"},{"key":"10.1016\/j.dld.2021.07.015_bib0020","unstructured":"European Medicines Agency. Doptelet [Internet]. 2019 [cited 2020 Apr 20]; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/doptelet"},{"key":"10.1016\/j.dld.2021.07.015_bib0021","unstructured":"National Institute for Health and Care Excellence. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | Guidance | NICE [Internet]. 2020. 1AD [cited 2020 Apr 20]; Available from: https:\/\/www.nice.org.uk\/guidance\/TA617\/chapter\/1-Recommendations"},{"issue":"7829","key":"10.1016\/j.dld.2021.07.015_bib0022","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.dld.2021.07.015_bib0023","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cgh.2018.11.047","article-title":"Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures","volume":"17","author":"Hidaka","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.07.015_bib0024","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00535-018-1499-2","article-title":"A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation","volume":"54","author":"Tateishi","year":"2019","journal-title":"Jpn J Gastroenterol"},{"issue":"4","key":"10.1016\/j.dld.2021.07.015_bib0025","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/hep.30561","article-title":"Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2)","volume":"70","author":"Peck-Radosavljevic","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.dld.2021.07.015_bib0026","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1053\/j.gastro.2018.05.025","article-title":"Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia","volume":"155","author":"Terrault","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.dld.2021.07.015_bib0027","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jhep.2014.07.007","article-title":"Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure","volume":"61","author":"Terrault","year":"2014","journal-title":"J Hepatol"},{"issue":"S1","key":"10.1016\/j.dld.2021.07.015_bib0028","first-page":"1093A","article-title":"Lusutrombopag for the management of thrombocytopenia in chronic liver disease patients (Pts) with comorbid obesity of diabetes [AASLD abstract 1813]","volume":"70","author":"Hassanein","year":"2019","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.dld.2021.07.015_bib0029","first-page":"265A","article-title":"Effectiveness and safety of thrombopoietin-receptor agonist lusutrombopag for chronic liver disease patients who undergo elective invasive procedures: results from a real-world, multicenter study [AASLD abstract 419]","volume":"70","author":"Taniki","year":"2019","journal-title":"Hepatology"},{"issue":"51","key":"10.1016\/j.dld.2021.07.015_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24510","article-title":"Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis","volume":"24","author":"Armstrong","year":"2020","journal-title":"Health Technol Assess"},{"issue":"7109","key":"10.1016\/j.dld.2021.07.015_bib0031","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br Med J"}],"updated-by":[{"DOI":"10.1016\/j.dld.2021.11.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000}}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821003844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821003844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T18:26:58Z","timestamp":1635186418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865821003844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1590865821003844"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2021.07.015","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2021.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. All rights reserved.","name":"copyright","label":"Copyright"}]}}